Predictive biomarkers for prostate cancer treatments


Long anticipated second-line therapies are now available for prostate cancer patients following the failure of classical androgen deprivation therapy. These include targeted therapies such as the PI3K inhibitor, BKM120 and Akt inhibitor AZD5363 and new hormonal agents targeting the androgen receptor (AR), including potent AR antagonists such as Enzalutamide and agents to inhibit androgen biosynthesis (eg Abiraterone).

However, there are no biomarkers available to predict which of these hormonal agents should be prescribed and which patients are most likely to respond to inhibition of the PI3K/Akt cascade in order to adopt a precision medicine approach. It is important to develop biomarkers to predict patient response and ensure maximum patient benefit with minimum unwanted toxicities.


We have identified a panel of biomarkers that are associated with poor clinical outcome in prostate cancer patients which will be employed to predict response to therapeutic intervention. We are establishing a bank of prostate cancer patient derived cell lines and xenografts to test whether our markers are associated with a response to these second line therapies.

Key benefits

  • targeted treatments to increase efficacy
  • avoid unnecessary side effects
  • eliminate inappropriate treatment costs

Markets & applications

  • treatment of prostate cancer
  • diagnosis of prostate cancer

Licensing & development

We're seeking partners for development as outlined above. Please contact Debbie Stack for further information.